Superior Multiplexing Capacity of PlexPrimers Enables Sensitive and Specific Detection of SNPs and Clustered Mutations in qPCR

Lit Yeen Tan, Samantha Michelle Walker, Tina Lonergan, Nicole Elizabeth Lima, Alison Velyian Todd, Elisa Mokany*

SpeeDx Pty Ltd, Eveleigh, NSW, Australia

* elisam@speedx.com.au

Abstract

Background

Whilst qPCR provides an extremely powerful tool for genetic analysis, some applications such as multiplexing variant alleles (eg SNPs, point mutations or deletions), remain challenging using current primer/probe systems. The novel design features of PlexPrimers allow sensitive, multiplexed analysis of variant alleles even when these are tightly clustered.

Method

PlexPrimers were combined with PlexZymes in qPCR assays for the detection of SNPs in human absorption, distribution, metabolism, and excretion (ADME) genes; clustered mutations in the 23S rRNA gene which confer antibiotic resistance to Mycoplasma genitalium; and deletions within the human epidermal growth factor receptor (EGFR) gene.

Results

The combination of PlexPrimers and PlexZymes allowed robust multiplexing of targets which resulted in 100% concordance with results obtained using hydrolysis probe kits for 14 SNPs in the ADME genes. A 7-plex qPCR assay targeting M. genitalium, 5 clustered mutations associated with macrolide resistance and an internal control, allowed efficient amplification of all targets, with all 5 mutations detected in a single channel. Finally, the strategy was employed to analyse common EGFR mutants with high sensitivity, detecting deletions present at only 0.01%.

Conclusion

PlexPrime is a novel technology for the detection of genetic variants. Unlike previous strategies, the combination of PlexPrimers with PlexZymes enables both allele-specific detection and allele-specific amplification in qPCR. The study demonstrated highly sensitive and specific detection of mutations and SNPs, and superior multiplexing capacity. The ability to multiplex clustered genetic variants reduces the time to result providing more actionable information.
Introduction

Real-time quantitative PCR (qPCR) is a powerful diagnostic technique which is widely used to detect and characterize sequences associated with human, animal or plant diseases. Assays may be designed to detect targets, such as viral or bacterial sequences to identify the cause of an infection, or alternatively they may be designed to distinguish specific sequence variations within genomes. These variations include inherited single nucleotide polymorphisms (SNPs) or acquired somatic mutations such as point mutations, deletions and insertions which are frequently associated with cancer. In bacteria, mutations may be associated with antibiotic resistance. Detection and characterisation of genomes affords broad clinical utility. It can assist in diagnosing disease, predicting response or resistance to therapy, determining prognosis, and allowing longitudinal disease monitoring. Multiplex qPCR is highly advantageous since it enables the analysis of multiple targets simultaneously, thereby increasing the amount of information per specimen and further allowing internal controls to be built in. Specific examples of targets of diagnostic significance include SNPs within ADME genes, which can affect drug efficacy and toxicity; mutations in the 23S rRNA gene of *Mycoplasma genitalium* which can confer resistance to azithromycin often used to treat sexually transmitted infections (STIs); and mutations in the EGFR gene which can predict response to cancer therapy.

PCR methods for allelic discrimination of SNPs and mutations employ various strategies. These include amplification by allele-specific primers, detection by allele-specific probes and/or determination of melting temperature profiles [1–3]. The Amplification Refractory Mutation System (ARMS), Mismatched Amplification Mutation Assay (MAMA), SuperSelective and Dual Priming Oligonucleotide (DPO) methods all employ “allele-specific primers” which target the amplification of specific variants that are complementary to their 3’ termini [4–7]. Resultant amplicons may be detected in real-time using generic hydrolysis probes or Molecular Beacons, which hybridize to a region which does not include the variant base [8,9]. Scorpion probes which are primer-probe hybrids can also use an ARMS approach for allele-specific amplification and detection [10,11]. However, since SNPs are variations in the same position, and mutations are often tightly clustered in hotspots of functional and structural importance, primer competition and cross-priming makes it difficult to develop multiplex assays using these approaches. Alternatively sequence variants can be amplified by generic primers, which do not selectively bind to the specific variant, and amplicons can subsequently detected and distinguished using “allele-specific probes” [12,13]. However, similar to the limitation with allele-specific primers, competition between allele-specific probes limits the number of clustered variants that can be analysed in a single reaction. Further, competition between either allele-specific primers or allele-specific probes generally decreases both specificity and sensitivity of detection. High resolution melt (HRM) analysis avoids this by differentiating on the basis of melt curve characteristics of specific alleles [12], but not all variants can be detected with equal ease and sensitivity. The method has greater difficulty distinguishing particular changes, for examples A to T and C to G, and vice versa, which result in relatively minor differences in the melting temperatures. Overall it remains challenging to sensitively and specifically detect variant alleles in a multiplex context using any of the above approaches.

This paper describes a new method for discrimination of variant sequences, which circumvents the limitations discussed above. The strategy combines allele-specific primer amplification using PlexPrimers with allele-specific detection using PlexZymes (also known as MNAzymes) [14,15]. The novel feature of PlexPrimers is that each contains an “insert sequence” (INS), which is non-complementary to the target initially but which is introduced into amplicons during amplification (Fig 1). The INS is positioned between 5’ and 3’ target-specific regions denoted as 5T and 3T respectively. For multiplexed mutation detection, each
PlexPrimer contains a different INS and is designed to be allele-specific via complementarity of the 3’ terminus of the 3T region with the target mutation. This strategy provides multiple advantages. Firstly, when the PlexPrimer binds initially, the INS effectively results in a shortening of the sequence at the 3’ end of each primer which is matched to the target. This increases the pressure for the polymerase to only extend primers matched at their termini, and in turn, this promotes highly stringent, selective amplification of specific mutant alleles. Secondly, the presence of unique INSs in the amplicons increases the ability to simultaneously multiplex targets since they reduce competition between allele-specific PlexPrimers. Finally, the INSs enhance the specificity of detection by reducing competition between allele-specific PlexZymes in real-time. This is achieved by designing each PlexZyme to have amplicon sensing regions that bind to the mutation, the INS and downstream target sequence. This paper demonstrates features and applications of this novel method and provides examples of their use in several settings where they provide advantages.

Materials and Methods

Standard qPCR conditions

Unless specified otherwise, the qPCR mixes contained 8 mM MgCl$_2$, 200 μM of each dNTP, 1x Immobuffer (Bioline) and 2 U MyTaqHS™ DNA polymerase (Bioline) in 25 μL final volume in 96 well plates on the CFX96™ (Bio-Rad Laboratories). These reactions were thermocycled at 95°C for 2 min followed by 10 cycles of 95°C for 15 s, 61°C for 60 s (-1°C per cycle) and 50 cycles at 95°C for 15 s, 52°C for 60 s.

ADME SNP genotyping

Templates. Fourteen ADME SNPs were genotyped using human genomic DNA (gDNA) templates listed in Table 1.

Oligonucleotides. The sequence of primers, partzymes and probes for the ADME assays are listed in Table A in S1 File for the bi-allelic assays and Table 2 for the tri-allelic assay. Bi-allelic multiplexed reactions contained oligonucleotide SNP components that were required for allele 1 and allele 2, or for both. Tri-allelic reactions contained additional SNP oligonucleotides that were required for the third allele. The oligonucleotide concentrations in a multiplex reaction were 400 nM of the Reverse primer and 400 nM of Partzyme B and for each allele in the reaction there was 40 nM Forward primer, 100 nM Partzyme A, and 200 nM Probe.

PlexPrime/PlexZyme qPCR assay. Standard qPCR conditions were used with the addition of 10 U of Ribosafe (Bioline) to the qPCR mix. Each reaction contained 5 ng of gDNA template or no-DNA.

TaqMan® drug metabolism genotyping assays. TaqMan® Drug metabolism genotyping assays (Thermo Fisher Scientific) (listed in Table 1) are commercial hydrolysis probe kits that were also used to genotype ADME SNPs. These were performed according to manufacturer’s instructions. Template DNA (5 ng) or no-DNA was added to each reaction. The reactions were performed in 25 μL final volume in 96 well plates on the CFX96™ (Bio-Rad Laboratories) and thermocycled at 95°C for 10 min followed by 50 cycles of 95°C for 15 s and 60°C for 60 s.

M. genitalium and mutations associated with azithromycin resistance

Templates. The MG 23S Positive Control kit (beta version) (SpeeDx Pty Ltd; Australia) contained quantitated synthetic DNA for the analysis of the M. genitalium MgPa and 23S rRNA genes (wild type A2058 and A2059 or mutant A2058G, A2058C, A2058T, A2059G, or A2059C Escherichia coli numbering) and an internal control template.
The MG 23S assay (beta version) (SpecDx Pty Ltd; Australia) contained all the components for the multiplexed amplification and detection of *M. genitalium* (*MgPa* gene) and five mutations in the 23S rRNA gene (A2058G, A2058C, A2058T, A2059G and A2059C) and the internal control. The assay was used according to the manufacturer's instructions in 20 μL final volume in 96 well plates run on the LC480 II (Roche Diagnostics). Reactions were thermocycled at 95˚C for 2 min, followed by 10 cycles of 95˚C for 5 s, 61˚C for 30 s (-0.5˚C per cycle), and 40 cycles of 95˚C for 5 s, 52˚C for 40 s. Ten-fold serial dilutions of 10^6 to 10^2 copies of *MgPa* and 23S rRNA templates in a background of 10^4 copies human genomic DNA (gDNA) (Promega) and internal control template were analysed. Control reactions, containing 10^6 copies of wild type (A2058 and A2059) template in a background of 10^4 copies human genomic DNA or no-DNA, were also performed. Analysis was performed according to the manufacturer’s instructions.

**PlexPrime/PlexZyme qPCR assay.** The MG 23S assay (beta version) (SpecDx Pty Ltd; Australia) contained all the components for the multiplexed amplification and detection of *M. genitalium* (*MgPa* gene) and five mutations in the 23S rRNA gene (A2058G, A2058C, A2058T, A2059G and A2059C) and the internal control. The assay was used according to the manufacturer’s instructions in 20 μL final volume in 96 well plates run on the LC480 II (Roche Diagnostics). Reactions were thermocycled at 95˚C for 2 min, followed by 10 cycles of 95˚C for 5 s, 61˚C for 30 s (-0.5˚C per cycle), and 40 cycles of 95˚C for 5 s, 52˚C for 40 s. Ten-fold serial dilutions of 10^6 to 10^2 copies of *MgPa* and 23S rRNA templates in a background of 10^4 copies human genomic DNA (gDNA) (Promega) and internal control template were analysed. Control reactions, containing 10^6 copies of wild type (A2058 and A2059) template in a background of 10^4 copies human genomic DNA or no-DNA, were also performed. Analysis was performed according to the manufacturer’s instructions.
EGFR deletions

**Template.** Plasmid templates were used to analyse EGFR deletions within exon 19, specifically c.2235-2249del and c.2236-2250del. Human wild type gDNA was extracted from the ATCC cell line A549 using the QIAamp DNA and Blood Mini Kit (Qiagen) according to the manufacturer's instructions.

**Oligonucleotides.** The sequences of primers, partzymes and the probe for amplification and detection of EGFR deletions c.2235-2249del and c.2236-2250del are listed in Table 3 along with the concentration used.

**PlexPrime/PlexZyme qPCR assay.** Standard qPCR conditions were used to analyse the c.2235-2249del and c.2236-2250del DNA plasmids (10^4, 10^3, 10^2 and 10 copies) diluted in a

---

### Table 1. DNA templates & comparator assays for analysis of ADME SNPs.

| Gene dbSNP ID | Allele #/base | DNA template used for testing SNPs | Comparator TaqMan SNP Genotyping Assay |
|---------------|---------------|-----------------------------------|---------------------------------------|
| **TPMT**      |               |                                   |                                      |
| rs56161402    | 1/C           | NA11830*                          | C__19569_20                          |
|               | 2/T           | nt                                |                                       |
| **CYP2C9**    |               |                                   |                                       |
| rs1799853     | 1/C           | NA18992*                          |                                       |
|               | 2/T           | nt                                |                                       |
| **CYP2C19**   |               |                                   |                                       |
| rs244285      | 1/A           | NA12891*; Calu-1*                 |                                       |
|               | 2/G           | NA11830*; NA18970*                |                                       |
| **CYP2C19**   |               |                                   |                                       |
| rs4986893     | 1/A           | nt                                |                                       |
|               | 2/G           | NA18970*; NA18992*                |                                       |
| **CYP2D6**    |               |                                   |                                       |
| rs5030655     | 1/del         | nt                                |                                       |
|               | 2/T           | NA11830*                          |                                       |
| **CYP2D6**    |               |                                   |                                       |
| rs1065852     | 1/C           | NA12248*; NA18608*; NA18855*; NA18992*; NA19003* | C__1148446_40 |
|               | 2/T           | NA18948*; IM-9*                   | C__3063403_10                          |
| **SLC22A2**   |               |                                   |                                       |
| rs316019      | 1/G           | NA18608*; NA18855*                | C__311180_20                          |
|               | 2/T           | nt                                |                                       |
| **SLCO1B3**   |               |                                   |                                       |
| rs4149117     | 1/G           | NA18573*; NA18948*                | C__25639181_40                        |
|               | 2/T           | NA18855*; NA18992*                |                                       |
| **CYP2C8**    |               |                                   |                                       |
| rs11572103    | 1/A           | nt                                | C__3063403_10                          |
|               | 2/T           | NA11830*                          |                                       |
| **CYP2C8**    |               |                                   |                                       |
| rs1058930     | 1/C           | NA18871*; NA18948*                | C__25761568_20                        |
|               | 2/G           | Calu-1*                           |                                       |
| **CYP2A6**    |               |                                   |                                       |
| rs1801272     | 1/A           | NA11830*                          | C__27861808_60                        |
|               | 2/T           | nt                                |                                       |
| **DPYD**      |               |                                   |                                       |
| rs1801265     | 1/C           | NA18855*; NA18871*                | C__3099976_30                          |
|               | 2/T           | NA18608*; Calu-1*                 |                                       |
| **CYP1B1**    |               |                                   |                                       |
| rs1056836     | 1/C           | NA18871*; SW480*                  | C__9491497_10                          |
|               | 2/G           | NA12891*; NA18948*                | C__3099976_30                          |
| **ABCB1**     |               |                                   |                                       |
| rs2032582     | 1/T           | nt                                | C__11711720D_40                        |
|               | 2/C           | NA18855; NA18871                  | C__11711720C_30                        |
|               | 3/A           | NA18573; NA18608                  |                                       |

nt—not tested.

* Human genomic DNA (gDNA) supplied by Coriell Cell Repositories.

* Human gDNA extracted from ATCC cell lines using the QIAamp DNA and Blood Mini Kit (Qiagen) using manufacturer’s instructions.

~ TaqMan® Drug metabolism genotyping assays (Thermo Fisher Scientific).

doi:10.1371/journal.pone.0170087.t001
background of $10^4$ copies of wild type A549 human gDNA thus producing reactions containing 100%, 10%, 1% and 0.1% of each deletion mutants respectively. In parallel $10^4$ copies of wild type A549 gDNA was analysed to determine specificity. To further test the detection limit of the plasmids ($10^3$, $10^2$ or $10$ copies) were diluted in $10^5$ copies of A549 gDNA producing reactions containing 1%, 0.1% and 0.01% mutant alleles, respectively. Wild type gDNA ($10^5$ copies) and no-DNA controls were analysed in parallel.

Results

Improved strategy for multiplex analysis of SNPs and mutations

A novel strategy was devised for the multiplexed detection of SNPs and clustered mutations (Figs 2 and 3). In this approach each variant was amplified using an allele-specific PlexPrimer that was matched with the variant base at its 3' terminus and contained a mismatched base near the terminus to increase specificity. Each allele-specific PlexPrimer contained a different, unique INS which was in one of three conformations with respect to the original target template. In the examples that follow the number of bases in the INS is ten and whilst all INSs are mismatched with respect to the target these ten bases may be either equal to (Planar Primers),

| SNP | Type of oligo | Sequence (5' to 3') | Modifications |
|-----|---------------|---------------------|--------------|
| Allele 1 | Forward primer | TAATCAATCATATTGATTTGACTCAAGACATACATCTCGCGTGA | - |
| | Partzyme A | AGACATACTAACCCCTTTGAAACACGAGGGAGGAT | 3' phosphate |
| | Probe 5 | ATACGGCTCgcwCCCCAGCTC | 5' F; 3' FQ |
| Allele 2 | Forward primer | TCTAATCATATATCTACTATAATATCTAGAATACGAGTGCTTGCTCGT | - |
| | Partzyme A | CACAAATGCATCTTTGCTGAAACAGGAGGAAA | 3' phosphate |
| | Probe 2 | AAGTTTTTTCGCgcwCCCACTGTC | 5' T; 3' RQ |
| Allele 3 | Forward primer | AAATTATTTACTCTACACAATTAAATACAAGATCGAGAGCTTCGCGTCTCCCTGCTC | - |
| | Partzyme A | ATGCGGAGACTTTTCTGCAAAAGGAGGAGA | 3' phosphate |
| | Probe 6 | CTTACTCTCTCgcwCCCACTGTC | 5' Q; 3' B2 |
| Alleles 1, 2, 3 | Reverse primer | ATGTATCTCGAGCAAGAGCAGTAGAA | - |
| | Partzyme B | GAGCTGCGAGCTCGCTGCTCGCT | 3' phosphate |

^ Ribonucleotide bases are in lower case and deoxyribonucleotide bases are in uppercase. The sequence complementary to the target is in italics, the variant alleles are in bold and italics, the mismatch is bold and the INS are bold and underlined. The other sequence comprises the rest of the PlexZyme, with underline denoting the probe binding sequence.

* Fluorophores used to label Probes are 6-FAM (F), Texas Red (T), and Quasar 705 (Q). Quenchers attached to the Probes are Black Hole Quencher 2 (B2), Iowa Black® FQ (FQ) and Iowa Black® RQ (RQ).

doi:10.1371/journal.pone.0170087.t002

Results

Improved strategy for multiplex analysis of SNPs and mutations

A novel strategy was devised for the multiplexed detection of SNPs and clustered mutations (Figs 2 and 3). In this approach each variant was amplified using an allele-specific PlexPrimer that was matched with the variant base at its 3' terminus and contained a mismatched base near the terminus to increase specificity. Each allele-specific PlexPrimer contained a different, unique INS which was in one of three conformations with respect to the original target template. In the examples that follow the number of bases in the INS is ten and whilst all INSs are mismatched with respect to the target these ten bases may be either equal to (Planar Primers),

| Type | Sequence (5' to 3') | Modifications | Concentration |
|------|---------------------|--------------|--------------|
| Probe 1 | ACCGCACCTCgcwC CCCAGCTC | 5' T, 3' RQ | 200 nM |
| Forward primer | GAGAAAGTTAAAAATTCGCTGCATACCAACAAAC | 40 nM |
| Reverse primer | CAGACATCGAGAAAAGGGCG | 200 nM |
| Partzyme A | AAATACCATGCTATCACAAACTCATCTCAGACGAGGCTCGGT | 3' phosphate | 100 nM |
| Partzyme B | GAGCTGCGAGCTCGCTGCTGCTCGC | 3' phosphate | 200 nM |

^ Ribonucleotide bases are in lower case and deoxyribonucleotide bases are in uppercase. The sequence complementary to the target is in italics, the INS are bold and underlined and the other sequence comprises the rest of the PlexZyme, with underline denoting the probe binding sequence.

* Fluorophore used to label the Probe is Texas Red (T) and the quencher attached to the Probe is Iowa Black® RQ (RQ).

doi:10.1371/journal.pone.0170087.t003
greater than (Loop) or less than (Target Loop) the number of unbound bases in the target sequence (Fig 3i, 3ii and 3iii). As a consequence of using PlexPrimers with INS in different conformations, the 5’ regions (5T) of each PlexPrimer bound to different regions in the target. The resultant amplicons therefore had substantial sequence differences, which included the variant base, the 3T mismatched base, the INS, and the 5T binding region.
This strategy greatly reduced competition between primers, and cross binding between different allelic primer/amplicon pairs, even in highly multiplexed assays which targeted a group of tightly clustered allelic variants. Further, it enabled PlexPrime amplicons to be simultaneously detected in qPCR with allele-specific PlexZymes, each of which bound to the variant base and the complement of the INS, as well as downstream amplified target sequence (Fig 3iv, 3v and 3vi). In some scenarios the PlexZymes were designed to cleave different universal probes (Fig 2i), each labelled with a different fluorophore. In this format the variant alleles could be individually identified in multiplexed reactions in a single well. Alternatively PlexZymes were designed to cleave the same universal probe (Fig 2(ii)), which allowed many variants to be multiplexed and detected through a single fluorescence channel. In this fashion, allele-specific PlexPrimers were coupled with allele-specific PlexZyme detection in multiplex qPCR.

Amplification and detection of SNPs in ADME genes

Multiplexed PlexPrime/PlexZyme assays were designed for 14 different SNPs within the ADME genes; of which twelve were bi-allelic, one was tri-allelic and one involved a deletion. Overall, characterisation of these SNPs involved discrimination of the full spectrum of alternate bases (G/A, G/T, G/C, A/T and C/T). The 14 ADME SNPs were analysed in 16 samples of gDNA using PlexPrime/PlexZyme assays and results were compared to commercial hydrolysis probe kits. The different gDNA samples showed homozygous and heterozygous genotypes.
plexPrime/PlexZyme assays showed 100% concordance (62/62) with results generated using hydrolysis probe assays (Table B in S1 File).

Whilst duplex detection of two variant alleles at one SNP can be easily achieved with various chemistries, the discrimination of three or more alleles simultaneously in one multiplex reaction is far more challenging. A single well, multiplex PlexPrime/PlexZyme assay for concurrent detection of each of the three different alleles was designed to genotype the tri-allelic ADME SNP, rs2032582 in the ABCB1 gene (Fig 3, Table 2). The assay combined three allele-specific PlexPrimers which had Planar, Loop and Target Loop conformations (Figs 2 and 3). These were simultaneously interrogated in real-time using three allele-specific PlexZymes, each capable of cleaving a unique universal probe. Since the probes where labelled with different fluorophores, the three alleles were able to be individually detected in three separate channels (Fig 2(i)). The triplex PlexPrime/PlexZyme assay showed 100% concordance with the two duplex hydrolysis probe assays in 9/9 samples, with the advantage that the tri-allelic SNPs could be identified in one well as opposed to two wells required for the two duplex hydrolysis probe assays. An example of amplification plots is shown in Fig 4 for 3 samples; NA18855 which is homozygous for the C allele, NA18608 which is homozygous for the T allele and NA18970 which is heterozygous for the T and A alleles. The triplex PlexPrime/PlexZyme assay generated steep amplification curves for all alleles, consistent with efficient amplification, and also allowed unambiguous discrimination between all three alleles. The amplification curves generated by the two hydrolysis probe assays were less steep suggesting lower amplification efficiency; however, they still discriminate between alleles (Fig 4).

Multiplexing clustered mutations

The superior capacity of PlexPrimers/PlexZymes for multiplexed mutation detection is further demonstrated in the MG 23S assay. This assay simultaneously detects *M. genitalium*, five mutations associated with azithromycin resistance, and an internal control. Specifically, this single well, 7-plex assay can simultaneously detect (i) the MgPa gene of *M. genitalium* in the first channel, (ii) any of five mutations present at positions 2058 and 2059 (*E. coli* numbering) of the 23S rRNA gene (A2058G, A2058C, A2058T, A2059G, and A2059C) in a second channel, and (iii) an internal control in a third channel. The internal control is non-homologous sequence which is added prior to extraction and is then co-extracted and co-amplified together with the targets. Any change in either extraction and/or amplification efficiency will be reflected both in the control and in the target gene and mutations.

In this multiplex assay, for the detection of the 23S rRNA mutations, five PlexPrimers targeting the five mutations were designed in the various formats; two had Loop and three had Target Loop conformations with 1, 6, 12, 17 and 23 bases unbound in the target sequence, respectively. The PlexPrimers were combined with allele-specific PlexZymes, all of which were designed to cleave the same common universal probe (illustrated in Fig 2(ii)). Analysis of serial dilutions demonstrated that all targets were detected robustly in multiplex with high efficiency; namely 94% for MgPa and between 95–105% for the 23S rRNA mutations (Fig 5 and Table C in S1 File). When a negative control reaction containing $10^6$ copies of the 23S rRNA wild type template was run it produced a non-specific background signal (Cq 21.1) which corresponds to a ΔCq of between 7.4 to 9.7 compared to Cq values for the same number of copies of each mutant template.

Highly sensitive detection of deletion mutations

The PlexPrime/PlexZyme strategy can also be used for highly sensitive detection of deletion mutations. A single PlexPrimer was designed to amplify the EGFR exon 19 deletion mutations, c.2235-2249del and c.2236-2250del. The performance of this assay was tested on a dilution
series for both of these deletions, with results showing sensitive detection of 10 copies in a background of wild type DNA equivalent to 0.1% sensitivity with efficiencies (and linearities) of 92% ($R^2 = 0.996$) and 97% ($R^2 = 0.998$) for the c.2235-2249del and c.2236-2250del templates, respectively (Table 4). Further experimentation showed that as little as 10 copies of both deletions could be detected in a background of $10^5$ copies of wild type alleles. The assay detected the deletions present in only 0.01% of total DNA (Fig 6), with very high specificity as evidenced by the lack of any background signal from $10^5$ copies of wild type alone.

**Discussion**

A new approach for the sensitive and specific, multiplexed amplification and detection of genetic variants has been demonstrated using PlexPrime amplification coupled with PlexZyme.
detection in qPCR. While qPCR is a rapid, inexpensive and highly sensitive molecular diagnostic tool, current technologies based on allele-specific primers or allele-specific probes alone are limited in their ability to detect variant alleles in multiplex. The unique design of the PlexPrime/PlexZyme system allows allele-specific priming to be coupled with allele-specific detection thus providing sensitive multiplex analysis of variants even when these are tightly clustered.

**Fig 5. Amplification plots for the MG 23S assay.** Analysis of serial dilutions (10⁶ to 10² copies in a background of human gDNA) showing detection of *M. genitalium* (MgPa gene) in channel 1 and five 23S rRNA mutations associated with azithromycin resistance (2058G, 2058C, 2058T, 2059G and 2059C) in channel 2. An internal control for monitoring reaction efficiency is read in channel 3. No-DNA control reactions were run in parallel. The amplification efficiency (E) of each target is indicated.

doi:10.1371/journal.pone.0170087.g005

**Table 4. Specific, sensitive detection of EGFR deletions using a single Plex Primer which selectively amplified multiple deletions.**

|                | EGFR c.2235-2249del mutant plasmid | EGFR c.2236-2250del mutant plasmid | EGFR Wild Type gDNA |
|----------------|------------------------------------|------------------------------------|---------------------|
| Cq 10⁸ copies (100%) | 17.3                               | 18.5                               | nd                  |
| Cq 10⁷ copies (10%)  | 21.0                               | 22.0                               | n/a                 |
| Cq 10⁶ copies (1%)   | 24.5                               | 25.4                               | n/a                 |
| Cq 10⁵ copies (0.1%) | 27.9                               | 28.7                               | n/a                 |
| Efficiency (%)       | 91.9                               | 96.7                               | n/a                 |
| R²                    | 0.99                               | 0.99                               | n/a                 |

nd—not detected. n/a—not applicable.

doi:10.1371/journal.pone.0170087.t004
SNP amplification and detection

The general capability of PlexPrimers to accurately amplify SNPs was demonstrated using genotyping assays for the ADME genes. These genes are important as they are involved in the absorption, distribution, metabolism and excretion of drugs, and polymorphisms can affect drug efficacy and toxicity. PlexPrime/PlexZyme results for 14 ADME SNPs were 100% concordant to commercial hydrolysis probe kits. Further, analysis of the tri-allelic SNP rs2032582 was achieved in a single triplex PlexPrime assay, whereas two duplex hydrolysis probe assays were required to genotype all three alleles. As such PlexPrimers can increase throughput and reduce costs since reagents are halved. Competition between allele-specific hydrolysis probes limits the ability to multiplex SNPs beyond duplex. In contrast, the design of the PlexPrimers significantly reduces competition at both the amplification step and the detection step, thus facilitating higher order multiplexed qPCR detection of SNPs or mutations.

The triplex ADME assay provides a demonstration of how this is achieved with allele-specific PlexPrimers, each of which has a unique INS that is configured to adopt a different conformation upon initial binding to the template. The unique INS either creates a loop within the primer (Loop), within the target (Target Loop) or is aligned parallel with respect to the target (Planar) (Fig 2i and Fig 3). Although the length of the different INSs is the same, the adoption of different conformations results in the 5T regions of each type of PlexPrime binding to different upstream target sequences. The three PlexPrime amplicons differ along the entire length of the 5’ primer binding region; namely the 5T target sequences, the INS sequences, and the allele-specific 3T termini (Fig 2). This increases primer specificity and reduces primer competition. Further, the short 3T region (approximately 10 bases) puts considerable pressure for highly selective binding and extension from the terminus at the annealing temperature of the PCR. Finally, since allele-specific partzymes (PzA) target unique INSs within amplicons, competition between PlexZymes is eliminated and targets can be multiplexed without loss of efficiency. The PlexPrime/PlexZyme system of combined allele-specific priming and detection enables robust, specific multiplexing with advantages that have been clearly demonstrated compared to protocols using either allele-specific priming or allele-specific detection.

Mutation detection in oncology

One field in which highly specific and highly sensitive mutation detection is of increasing clinical importance is oncology. Genes that activate specific signalling pathways can provide actionable targets for therapies, and companion diagnostic tests can determine if patients are...
likely, or unlikely, to benefit from treatment. For example, patients with metastatic colorectal cancer who have KRAS mutations would not be expected to respond to anti-EGFR therapies such as cetuximab, whereas patients with metastatic melanoma who have a BRAF mutation may be suitable for anti-BRAF therapies such as vemurafenib and dabrafenib.

High level, highly specific multiplexing of oncogene mutations using PlexPrime/PlexZyme technology has been reported on the Biocartis Idylla™ system [16]. The Idylla™ is a fully integrated and automated molecular diagnostic platform which can perform sample preparation, qPCR and reporting within two hours. In that study a single Idylla™ cartridge facilitated detection of 18 mutations; 13 mutations in the KRAS gene and 5 mutations in the BRAF gene. Results demonstrated excellent specificity and minimal cross-reactivity for all targets. The assay was evaluated on a set of colon cancer and melanoma FFPE samples and results were >96% concordant with those from sequencing.

Closer examination of the performance of that Idylla assay indicates that the PlexPrime/PlexZyme combination is not only easier to multiplex but is also inherently more specific than alternate techniques. Cross-reactivity was measured by calculating the difference in the number of cycles between specific amplification by a primer with its matched mutant target and the non-specific signal from other unmatched mutant templates. The PlexPrime assay, detecting 18 mutations in a single Idylla™ cartridge, showed excellent specificity and cross-reactivity for all KRAS targets, with delta Cq values of > 7 between mutants and > 12 between each mutant and the wild type [16]. An alternative ARMS-Scorpion assay, which requires seven parallel singleplex assays to analyse seven mutations in the G12 and G13 codon hotspots of KRAS [17] reported significant cross-reactivity between KRAS mutants which was observed within < 3 cycles in 1 case and within < 7 cycles in 3 cases). Since the basic difference between an ARMS primer and a PlexPrimer is the presence of the INS sequence, this observation lends support to the hypothesis that a short terminal sequence, which is a consequence of introducing the INS sequence, results in greater selective pressure for primers to only extend templates when they are terminally matched. This advantage has also been reported in DPO and Super-Selective primers which incorporate polydeoxyinosine linkers or non-complementary bridges respectively near the 3’ termini of the primers [6,7]. However, the PlexPrime/PlexZyme strategy has an additional unique advantage in that it has been demonstrated to support higher level multiplexing together with detection mediated by binding to the unique INSs.

PlexPrime is not only useful for detection of SNPs and somatic point mutations but can also detect other mutations such as deletions and insertions. EGFR deletion mutations are often found in patients with non-small cell lung cancer (NSCLC) and 48% of these are exon 19 deletion mutations [18]. There are many therapies targeted at EGFR, and exon 19 deletions confer greater sensitivity to EGFR tyrosine kinase inhibitors. In our study a single PlexPrimer/PlexZyme combination was designed to target both of the two most common deletions, c.2235-2249del and c.2236-2250del. This assay was shown to be exquisitely sensitive, detecting 10 copies of the deletion mutants in 10^5 copies of wild-type, equivalent to 0.01% sensitivity.

An Italian group recently reported results wherein a cohort of lung cancer cytological specimens where analysed using the Idylla™ EGFR Mutation assay (Biocartis), which detects 53 different mutations (point mutations, insertions and deletions) using integrated PlexPrime/PlexZyme technology. The system yielded valid results in 74/76 (97.3%) samples, with a sensitivity of 100% percent (n = 32). Further, the system revealed two additional point mutations and two addition deletions in EGFR which had been not been detected by their standard reference methods (Fragment length electrogram and TaqMan). Their study concluded the Idylla assay and platform enabled very rapid decision making with high sensitivity, large reference range and ease of use even in less experienced laboratories [19]. Likewise, Solassol et al...
reported similar clinical utility and convenience reporting that the Idylla KRAS Mutation Test afforded simple, highly reliable and rapid routine determination of KRAS mutational status to guide colorectal therapy [20].

Greater sensitivity of mutation detection is becoming increasingly important for the analysis of cancer samples [21,22], and cellular heterogeneity of solid tumours has implications for the development of drug resistance. Subpopulations of cells with advantageous mutations, which are initially present in low abundance, may be selected for during treatment. This can lead to clonal expansion resulting in reduced progression-free survival times and recurrence of disease [23,24]. Therefore, more sensitive techniques which detect low prevalence mutations in heterogeneous tumour tissue samples may better predict patient response to a targeted therapy. Liquid biopsies have been shown to contain circulating tumour cells (CTCs) or cell-free tumour DNA (cfDNA) shed from the primary or metastatic tumours into blood. These samples offer a non-invasive method for earlier detection and serial sampling for disease monitoring [23], and are more likely to capture tumour heterogeneity. However, liquid biopsies also contain an abundance of non-tumour cells or DNA and thus highly sensitive techniques are required to detect the relatively rare CTCs and cfDNA. The very high sensitivity of PlexPrime demonstrated in our study makes it particularly well suited for detecting minor emerging clonal populations and/or for monitoring disease using liquid biopsies. The true power of combining PlexPrime and PlexZyme is evidenced in Biocartis’ Idylla oncology menu which includes three cartridges that collectively analyse 98 mutations; namely 21 mutations in a KRAS Test (CE-IVD); 25 Mutations in a NRAS-BRAF-EGFR Test (CE-IVD) and 52 mutations in a EGFR Mutation Assay (RUO); and further with the recent release of the liquid biopsy Idylla™ ctKRAS Mutation Assay (RUO).

Rapid amplification and detection of clustered variants

In another application, PlexPrime/PlexZyme was used to stack the detection of five clustered mutations in a single channel on a standard qPCR machine. *M. genitalium* is an emerging sexually transmitted bacterium, and mutations in the 23S rRNA gene at positions 2058 and 2059 (*E. coli* numbering) have been associated with treatment failure and resistance to azithromycin, a macrolide antibiotic [25–27]. A single well 7-plex/3-channel assay was used to simultaneously detect *M. genitalium* (channel 1), 5 mutations associated with resistance to azithromycin (channel 2), plus an internal control (channel 3). Comparison of the single target mutation assays to performance in the 7-plex reaction over a 5-log range, showed a minor change in efficiency of 94% to 95%, 94% to 95%, 96% to 95%, 95% to 99% and 98% to 105% for A2058G, A2058C, A2058T, A2059G, A2059C, respectively. Further, detection of 40 copies for each target was similar and the cross-reactivity between mutant signal and wild type signal was always greater than 7 cycles.

The five 23S rRNA mutations are all associated with resistance to azithromycin; hence stacking the readout of the resistance mutations in a single well allows rapid screening in a scenario where knowledge of which specific individual mutation is not required. Software provided with the kit uses an algorithm based on the ΔCq between total *M. genitalium* (channel 1) and 23S rRNA signals (Channel 2) to automate sample result interpretation and ensure mutants are correctly called so as to avoid false positive results. This software has been validated on clinical specimens with results published in Tabrizi et al [26].

These types of multiplex assays have great potential to increase throughput in pathology laboratories which run a battery of qPCR-based assays. This assay has since been validated on several hundred urine and urogenital samples with very high clinical sensitivity and specificity [28].
Conclusion

Although PlexPrimers could be used with other detection technologies such as hybridisation probes and Molecular Beacons, it is only when coupled with PlexZyme qPCR, that it uniquely enables the combination of allele-specific priming and allele-specific detection. This strategy enables superior multiplexing capacity with sensitive and specific detection, as demonstrated for SNPs and mutations. PlexPrime/PlexZyme qPCR is a rapid, inexpensive, robust, sensitive and specific method, making it a viable molecular diagnostic tool.

Supporting Information

S1 File. Table A. PCR primers, partzymes and probes for ADME SNP assays. Table B. PlexPrime/PlexZyme assays results for ADME SNPs. Table C. PlexPrime/PlexZyme assay results for amplification of MgPa and 23S rRNA genes in serially diluted samples.

Author Contributions

Conceptualization: EM AT LT.

Formal analysis: EM AT LT TL SW NL.

Funding acquisition: AT EM.

Investigation: EM LT TL SW NL.

Methodology: EM AT LT TL SW NL.

Project administration: EM AT LT.

Software: LT SW EM.

Supervision: EM AT LT.

Validation: EM AT LT TL SW NL.

Visualization: EM AT LT.

Writing – original draft: EM AT LT.

Writing – review & editing: EM AT LT.

References

1. Milbury CA, Li J, Makrigiorgos GM. PCR-based methods for the enrichment of minority alleles and mutations. Clin Chem. 2009; 55: 632–640. doi: 10.1373/clinchem.2008.113035 PMID: 19201784

2. Chen X, Sullivan PF. Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughput. Pharmacogenomics J. 2003; 3: 77–96. doi: 10.1038/sj.tpj.6500167 PMID: 12746733

3. Vossen RHAM, Aten E, Roos A, Den Dunnen JT. High-resolution melting analysis (HRMA)—More than just sequence variant screening. Hum Mutat. 2009; 30: 860–866. doi: 10.1002/humu.21019 PMID: 19418555

4. Newton CR, Graham a, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989; 17: 2503–2516. PMID: 2785681

5. Cha RS, Zarbl H, Keohavong P, Thilly WG. Mismatch amplification mutation assay (MAMA): application to the c-ras gene. PCR Methods Appl. 1992; 2: 14–20. PMID: 1490171

6. Chun JY, Kim KJ, Hwang IT, Kim YJ, Lee DH, Lee IK, et al. Dual priming oligonucleotide system for the multiplex detection of respiratory viruses and SNP genotyping of CYP2C19 gene. Nucleic Acids Res. 2007; 35: 6–11.
7. Vargas DY, Kramer FR, Tyagi S, Marras SAE. Multiplex Real-Time PCR Assays that Measure the Abundance of Extremely Rare Mutations Associated with Cancer. PLoS One. 2016; 11: e0156546. doi: 10.1371/journal.pone.0156546 PMID: 27244445
8. Li B, Kadura I, Fu DJ, Watson DE. Genotyping with TaqMAMA. Genomics. 2004; 83: 311–320. PMID: 14706460
9. Clayton SJ, Scott FM, Walker J, Callaghan K, Haque K, Liloglou T, et al. K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification. Clin Chem. 2000; 46: 1929–38. PMID: 11106325
10. Board RE, Thelwell NJ, Ravetto PF, Little S, Ranson M, Dive C, et al. Multiplexed assays for detection of mutations in PIK3CA. Clin Chem. 2008; 54: 757–60. doi: 10.1373/clinchem.2007.098376 PMID: 18375489
11. Laosinchi-Wolf W, Ye F, Tran V, Yang Z, White R, Bloom K, et al. Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens. J Clin Pathol. 2011; 64: 30–6. doi: 10.1136/jcp.2010.081539 PMID: 21030527
12. Malkki M, Petersdorf EW. Genotyping of single nucleotide polymorphisms by 5'??? nuclease allelic discrimination. Methods Mol Biol. 2012; 882: 173–182. doi: 10.1007/978-1-61779-842-9_10 PMID: 22665234
13. Piatak AS, Tyagi S, Pol AC, Telenti A, Miller LP, Kramer FR, et al. Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis. Nat Biotechnol. 1998; 16: 359–63. doi: 10.1038/nbt0498-359 PMID: 9555727
14. Mokany E, Bone SM, Young PE, Doan TB, Todd AV. MNAzyme qPCR with superior multiplexing capacity. Clin Chem. 2013; 59: 419–426. doi: 10.1373/clinchem.2012.192930 PMID: 23232065
15. Mokany E, Bone SM, Young PE, Doan TB, Todd AV. MNAzymes, a versatile new class of nucleic acid enzymes that can function as biosensors and molecular switches. J Am Chem Soc. 2010; 132: 1051–1059. doi: 10.1021/ja9076777 PMID: 20038095
16. Vandenbroucke I, Vermeiren K, Mokany E, Tan LY, Lima N, Walker S, et al. A rapid and fully automated multiplex assay for KRAS-BRAF mutations with high mutation sensitivity using novel selective amplification and detection technologies [Internet]. Poster presented at AACR 2014.
17. Qiagen. therascreen® KRAS RGQ PCR Kit Instructions for Use (Handbook). 2012. pp. 1–88.
18. Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 2010; 277: 301–8. doi: 10.1111/j.1742-4658.2009.07448.x PMID: 19922469
19. De Luca C, Gragnano G, Pisapia P, Viglieri E, Malapelle U, Bellevicine C and Troncone G. EGFR mutation detection on routine cytological smears of non-small cell lung cancer by digital PCR: A validation study. J Clin Pathol. 2016 Aug 19.
20. Melchior L, Grauslund M, Bellosillo B, Montagut C, Torres E, Moragon E, et al. Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma. Exp Mol Pathol. 2015 Dec; 99(3):485–91 doi: 10.1016/j.yexmp.2015.09.004 PMID: 26407762
21. Sorensen BS, Wu L, Wei W, Tsai J, Weber B, Nexo E, et al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer. 2014; 120: 3896–901. doi: 10.1002/cncr.28964 PMID: 25103305
22. Oxnard GR, Paweletz CP, Kuang Y, Mach SL, Torres E, Moragon E, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014; 20: 1698–705. doi: 10.1158/1078-0432.CCR-13-2482 PMID: 24429876
23. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013; 10: 472–84. doi: 10.1038/nrclinonc.2013.110 PMID: 23836314
24. Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol. Elsevier B.V; 2014; 8: 1095–1111. doi: 10.1016/j.molonc.2014.06.005 PMID: 25087573
25. Twin J, Jensen JS, Bradshaw CS, Garland SM, Fairley CK, Min LY, et al. Transmission and selection of macrolide resistant mycoplasma genitalium infections detected by rapid high resolution melt analysis. PLoS One. 2012; 7: 1–8.
26. Jensen JS. Protocol for the detection of Mycoplasma genitalium by PCR from clinical specimens and subsequent detection of macrolide resistance-mediated mutations in region V of the 23S rRNA gene. Methods Mol Biol. 2012; 903: 129–39. doi: 10.1007/978-1-61779-937-2_8 PMID: 22782815
27. Bissessor M, Tabrizi SN, Twin J, Abdoh H, Fairley CK, Chen MY, et al. Macrolide Resistance and Azithromycin Failure in a Mycoplasma genitalium-Infected Cohort and Response of Azithromycin Failures
28. Tabrizi SN, Tan LY, Walker S, Twin J, Poljak M, Bradshaw CS, et al. Multiplex Assay for Simultaneous Detection of Mycoplasma genitalium and Macrolide Resistance Using PlexZyme and PlexPrime Technology. PLoS One. 2016; 11: e0156740. doi: 10.1371/journal.pone.0156740 PMID: 27271704